We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

91 hedge funds and large institutions have $144M invested in Ovid Therapeutics in 2020 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 22 increasing their positions, 29 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 12

63% more call options, than puts

Call options by funds: $760K | Put options by funds: $465K

15% more funds holding

Funds holding: 79 → 91 (+12)

0.25% less ownership

Funds ownership: 39.91% → 39.66% (-0.25%)

11% less capital invested

Capital invested by funds: $161M → $144M (-$17.1M)

24% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 29

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
91
Holders Change
+12
Holders Change %
+15.19%
% of All Funds
1.84%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
24
Increased
22
Reduced
29
Closed
12
Calls
$760K
Puts
$465K
Net Calls
+$295K
Net Calls Change
-$39K

Top Buyers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
+$16.7M
2
VC
Vivo Capital
California
+$8.36M
3
BI
BVF Inc
California
+$8.23M
4
SI
Sofinnova Investments
California
+$7.34M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$3.18M

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$18.9M
2
Invesco
Invesco
Georgia
-$4.98M
3
Renaissance Technologies
Renaissance Technologies
New York
-$4.6M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$3.76M
5
Millennium Management
Millennium Management
New York
-$3.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
Squarepoint
26
Squarepoint
New York
$808K +$942K +140,718 New
Morgan Stanley
27
Morgan Stanley
New York
$744K -$143K -21,361 -14%
RG
28
Redmile Group
California
$700K – – –
FC
29
Fairpointe Capital
Illinois
$699K -$33.5K -5,000 -4%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$698K -$6.81K -1,018 -0.8%
EI
31
EAM Investors
California
$695K -$426K -63,612 -34%
Citadel Advisors
32
Citadel Advisors
Florida
$579K +$527K +78,730 +357%
Charles Schwab
33
Charles Schwab
California
$560K -$22.8K -3,412 -3%
California Public Employees Retirement System
34
California Public Employees Retirement System
California
$559K +$17.4K +2,600 +3%
First Trust Advisors
35
First Trust Advisors
Illinois
$530K +$618K +92,382 New
Los Angeles Capital Management
36
Los Angeles Capital Management
California
$409K -$60.1K -8,980 -11%
State of Wisconsin Investment Board
37
State of Wisconsin Investment Board
Wisconsin
$397K +$462K +69,100 New
California State Teachers Retirement System (CalSTRS)
38
California State Teachers Retirement System (CalSTRS)
California
$372K +$1.39K +207 +0.3%
VEA
39
Virtus ETF Advisers
New York
$337K -$53.5K -8,001 -12%
GCP
40
GSA Capital Partners
United Kingdom
$326K +$381K +56,874 New
AllianceBernstein
41
AllianceBernstein
Tennessee
$322K – – –
OMC
42
Old Mission Capital
Illinois
$317K +$369K +55,200 New
Dimensional Fund Advisors
43
Dimensional Fund Advisors
Texas
$303K – – –
Goldman Sachs
44
Goldman Sachs
New York
$296K -$423K -63,161 -55%
AQR Capital Management
45
AQR Capital Management
Connecticut
$291K +$339K +50,634 New
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$266K -$13K -1,945 -4%
Jacobs Levy Equity Management
47
Jacobs Levy Equity Management
New Jersey
$234K +$272K +40,717 New
TRCT
48
Tower Research Capital (TRC)
New York
$233K +$257K +38,421 +1,808%
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
$225K – – –
Jane Street
50
Jane Street
New York
$201K +$37.7K +5,632 +19%
1
2
3 4 5

OVID Hedge Fund Activity: Q3 2020 in Review

91 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q3 2020, worth a combined $144M — down 11% from $161M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new OVID positions and 12 closed out — a net gain of 12 holders — while 22 added to existing stakes and 29 trimmed.

The largest buyer was Artal Group, opening a new position worth an estimated $16.7M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $18.9M sold.

  • 91 institutional investors held Ovid Therapeutics (OVID) as of Q3 2020, up from 79 in Q2 2020.
  • Funds reported $144M of Ovid Therapeutics stock for Q3 2020, down 11% quarter-over-quarter.
  • 24 funds opened new Ovid Therapeutics positions in Q3 2020 and 12 closed out, a net change of +12 holders.
  • The largest Ovid Therapeutics buyer in Q3 2020 was Artal Group, an estimated $16.7M added.
  • The largest Ovid Therapeutics seller in Q3 2020 was Consonance Capital Management, an estimated $18.9M sold.

Based on aggregated 13F filings for Q3 2020.